Celon Pharma SA Working Capital to Net Assets Ratio
Celon Pharma SA working capital to net assets ratio. Celon Pharma SA (CLN) has a Working Capital to Net Assets ratio of 3.4% as of March 2026. Working capital of zł17.85 Million (current assets of zł105.44 Million minus current liabilities of zł87.60 Million) is measured against net assets of zł528.78 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Celon Pharma SA (2012–2025)
Working capital to net assets ratio of Celon Pharma SA from 2012 to 2025. This chart shows how Celon Pharma SA's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 3.4%, reflecting working capital of zł17.85 Million against net assets of zł528.78 Million PLN. See CLN defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Celon Pharma SA Working Capital to Net Assets Ratio by Year (2012–2025)
Celon Pharma SA working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Celon Pharma SA from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Celon Pharma SA.
| Year | WC/NA Ratio | Working Capital (PLN) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 10.2% | zł38.99 Million | zł382.99 Million | zł102.26 Million | zł63.27 Million | ▼ -6.3 pp |
| 2024 | 16.5% | zł73.30 Million | zł445.21 Million | zł160.43 Million | zł87.12 Million | ▼ -6.7 pp |
| 2023 | 23.2% | zł103.41 Million | zł445.56 Million | zł189.75 Million | zł86.34 Million | ▼ -2.0 pp |
| 2022 | 25.3% | zł121.14 Million | zł479.65 Million | zł237.58 Million | zł116.44 Million | ▼ -9.5 pp |
| 2021 | 34.7% | zł192.34 Million | zł554.00 Million | zł278.70 Million | zł86.36 Million | ▲ +33.6 pp |
| 2020 | 1.1% | zł4.77 Million | zł434.67 Million | zł118.92 Million | zł114.15 Million | ▼ -25.3 pp |
| 2019 | 26.4% | zł117.59 Million | zł445.04 Million | zł143.58 Million | zł25.98 Million | ▼ -16.8 pp |
| 2018 | 43.2% | zł194.03 Million | zł448.73 Million | zł213.75 Million | zł19.72 Million | ▼ -10.3 pp |
| 2017 | 53.6% | zł235.57 Million | zł439.85 Million | zł254.55 Million | zł18.97 Million | ▼ -10.0 pp |
| 2016 | 63.6% | zł255.92 Million | zł402.50 Million | zł270.16 Million | zł14.24 Million | ▲ +55.3 pp |
| 2015 | 8.3% | zł8.39 Million | zł100.82 Million | zł44.95 Million | zł36.55 Million | ▼ -7.1 pp |
| 2014 | 15.4% | zł10.74 Million | zł69.62 Million | zł29.05 Million | zł18.30 Million | ▼ -15.4 pp |
| 2013 | 30.9% | zł16.11 Million | zł52.20 Million | zł26.80 Million | zł10.68 Million | ▲ +24.8 pp |
| 2012 | 6.0% | zł3.35 Million | zł55.57 Million | zł17.57 Million | zł14.22 Million | — |